MYOM3: A Potential Drug Target and Biomarker for Skeletal Muscles

Target Name: MYOM3

NCBI ID: G127294

MYOM3

MYOM3: A Potential Drug Target and Biomarker for Skeletal Muscles

Myomesin family member 3 (MYOM3) is a protein that plays a crucial role in the structure and function of skeletal muscles. It is a member of the myomesin family, which is known for their ability to regulate muscle size and strength. In this article, we will discuss the research on MYOM3 and its potential as a drug target or biomarker.

Structure and Function

MYOM3 is a 20-kDa protein that is expressed in muscle fibers and is responsible for the myofibrillar organization of muscle cells. It is composed of a unique nucleotide-rich region, a transmembrane region, and an N-terminus region that contains a myosin regulatory protein (Myosin light chain) domain.

The function of MYOM3 is to regulate the size and strength of muscle fibers. It does this by interacting with the Myosin light chain, which is the protein that binds to and activates the myosin ATPase. Activation of the myosin light chain allows the muscle fibers to contract and relax properly, leading to increased muscle strength.

MYOM3 has been shown to play a role in the regulation of muscle size and strength in various organisms, including humans. For example, studies have shown that MYOM3 is involved in the regulation of muscle mass in mice and that it is downregulated in muscle fibers with age.

Potential as a Drug Target

MYOM3 has also been shown to be a potential drug target.MYOM3 has been shown to interact with various drug molecules, including rapamycin and the myosin light chain inhibitor K+ channels. These interactions suggest that MYOM3 may be a useful target for drugs that target the myosin system.

One of the potential benefits of targeting MYOM3 is its potential to improve muscle strength and mass in diseases such as muscle-wasting disorders and myopathies. For example, studies have shown that MYOM3 is downregulated in muscle fibers with muscle-wasting disorders, and that inhibition of MYOM3 has been shown to increase muscle mass in these disorders.

Another potential benefit of targeting MYOM3 is its potential to treat myopathies, such as dystrophia. Myopathies are a group of genetic disorders that are characterized by muscle weakness and dysfunction. MYOM3 has been shown to be involved in the regulation of muscle size and strength in myopathies , and inhibition of MYOM3 has been shown to improve muscle function in these disorders.

Biomarker Potential

MYOM3 has also been shown to be a potential biomarker for muscle health. The myosin light chain is a well-established biomarker for muscle strength and function, and its activity can be used as a marker for muscle health.MYOM3 is a known interactor with the myosin light chain, and therefore it may be a useful biomarker for tracking muscle health in diseases such as muscle-wasting disorders and myopathies.

Conclusion

MYOM3 is a protein that plays a crucial role in the structure and function of skeletal muscles. It is a member of the myomesin family and is responsible for the myofibrillar organization of muscle cells. MYOM3 has been shown to play a role in the regulation of muscle size and strength in various organisms, including humans. As a potential drug target and biomarker, MYOM3 has the potential to improve muscle strength and mass in diseases such as muscle-wasting disorders and myopathies. Further research is needed to fully understand the role of MYOM3 in muscle biology and to develop effective treatments.

Protein Name: Myomesin 3

Functions: May link the intermediate filament cytoskeleton to the M-disk of the myofibrils in striated muscle

The "MYOM3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MYOM3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets